{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T17:39:30Z","timestamp":1789666770141,"version":"4.0.1"},"update-to":[{"DOI":"10.1371\/journal.pntd.0011635","type":"new_version","label":"New version","source":"publisher","updated":{"date-parts":[[2024,4,26]],"date-time":"2024-04-26T00:00:00Z","timestamp":1714089600000}}],"reference-count":95,"publisher":"Public Library of Science (PLoS)","issue":"4","license":[{"start":{"date-parts":[[2024,4,16]],"date-time":"2024-04-16T00:00:00Z","timestamp":1713225600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000865","name":"Bill and Melinda Gates Foundation","doi-asserted-by":"publisher","award":["INV-004713"],"award-info":[{"award-number":["INV-004713"]}],"id":[{"id":"10.13039\/100000865","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["www.plosntds.org"],"crossmark-restriction":false},"short-container-title":["PLoS Negl Trop Dis"],"abstract":"<jats:sec id=\"sec001\">\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Post-kala-azar dermal leishmaniasis (PKDL) is a dermatosis which can occur after successful treatment of visceral leishmaniasis (VL) and is a public health problem in VL endemic areas. We conducted a systematic scoping review to assess the characteristics of published PKDL clinical studies, understand the scope of research and explore the feasibility and value of developing a PKDL individual patient data (IPD) platform.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"sec002\">\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      A systematic review of published literature was conducted to identify PKDL clinical studies by searching the following databases: PubMed, Scopus, Ovid Embase, Web of Science Core Collection, WHO Global Index Medicus, PASCAL,\n                      <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"http:\/\/clinicaltrials.gov\/\" xlink:type=\"simple\">Clinicaltrials.gov<\/jats:ext-link>\n                      , Ovid Global Health, Cochrane Database and CENTRAL, and the WHO International Clinical Trials Registry Platform. Only prospective studies in humans with PKDL diagnosis, treatment, and follow-up measurements between January 1973 and March 2023 were included. Extracted data includes variables on patient characteristics, treatment regimens, diagnostic methods, geographical locations, efficacy endpoints, adverse events and statistical methodology.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"sec003\">\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>A total of 3,418 records were screened, of which 56 unique studies (n = 2,486 patients) were included in this review. Out of the 56 studies, 36 (64.3%) were from India (1983\u20132022), 12 (21.4%) from Sudan (1992\u20132021), 6 (10.7%) were from Bangladesh (1991\u20132019), and 2 (3.6%) from Nepal (2001\u20132007). Five (8.9%) studies were published between 1981\u20131990 (n = 193 patients), 10 (17.9%) between 1991\u20132000 (n = 230 patients), 10 (17.9%) between 2001\u20132010 (n = 198 patients), and 31 (55.4%) from 2011 onwards (n = 1,865 patients). Eight (14.3%) were randomised clinical trials, and 48 (85.7%) were non-randomised studies. The median post-treatment follow-up duration was 365 days (range: 90\u2013540 days) in 8 RCTs and 360 days (range: 28\u20132,373 days) in 48 non-randomised studies. Disease diagnosis was based on clinical criterion in 3 (5.4%) studies, a mixture of clinical and parasitological methods in 47 (83.9%) and was unclear in 6 (10.7%) studies. Major drugs used for treatment were miltefosine (n = 636 patients), liposomal amphotericin B (L-AmB) (n = 508 patients), and antinomy regimens (n = 454 patients). Ten other drug regimens were tested in 270 patients with less than 60 patients per regimen.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"sec004\">\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Our review identified studies with very limited sample size for the three major drugs (miltefosine, L-AmB, and pentavalent antimony), while the number of patients combined across studies suggest that the IPD platform would be valuable. With the support of relevant stakeholders, the global PKDL community and sufficient financing, a PKDL IPD platform can be realised. This will allow for exploration of different aspects of treatment safety and efficacy, which can potentially guide future healthcare decisions and clinical practices.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1371\/journal.pntd.0011635","type":"journal-article","created":{"date-parts":[[2024,4,16]],"date-time":"2024-04-16T14:27:56Z","timestamp":1713277676000},"page":"e0011635","update-policy":"https:\/\/doi.org\/10.1371\/journal.pntd.corrections_policy","source":"Crossref","is-referenced-by-count":9,"title":["Post-kala-azar dermal leishmaniasis (PKDL) drug efficacy study landscape: A systematic scoping review of clinical trials and observational studies to assess the feasibility of establishing an individual participant-level data (IPD) platform"],"prefix":"10.1371","volume":"18","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2892-3053","authenticated-orcid":true,"given":"Sauman","family":"Singh-Phulgenda","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rishikesh","family":"Kumar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Prabin","family":"Dahal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abdalla","family":"Munir","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sumayyah","family":"Rashan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rutuja","family":"Chhajed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caitlin","family":"Naylor","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brittany J.","family":"Maguire","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Niyamat Ali","family":"Siddiqui","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eli","family":"Harriss","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manju","family":"Rahi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fabiana","family":"Alves","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shyam","family":"Sundar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kasia","family":"Stepniewska","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ahmed","family":"Musa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philippe J.","family":"Guerin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Krishna","family":"Pandey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"340","published-online":{"date-parts":[[2024,4,16]]},"reference":[{"key":"pntd.0011635.ref001","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1016\/S1473-3099(03)00517-6","article-title":"Post-kala-azar dermal leishmaniasis","volume":"3","author":"EE Zijlstra","year":"2003","journal-title":"Lancet Infect Dis"},{"key":"pntd.0011635.ref002","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1517\/14656566.2015.973850","article-title":"An update on pharmacotherapy for leishmaniasis","volume":"16","author":"S Sundar","year":"2015","journal-title":"Expert Opin Pharmacother"},{"key":"pntd.0011635.ref003","doi-asserted-by":"crossref","first-page":"24","DOI":"10.4103\/ijd.IJD_602_20","article-title":"Post Kala-Azar Dermal Leishmaniasis: Clinical Features and Differential Diagnosis.","volume":"66","author":"P Kumar","year":"2021","journal-title":"Indian J Dermatol"},{"key":"pntd.0011635.ref004","doi-asserted-by":"crossref","first-page":"e0005391","DOI":"10.1371\/journal.pntd.0005391","article-title":"Asymptomatic leishmaniasis in kala-azar endemic areas of Malda district, West Bengal, India.","volume":"11","author":"P Saha","year":"2017","journal-title":"PLoS Negl Trop Dis"},{"key":"pntd.0011635.ref005","doi-asserted-by":"crossref","first-page":"e0005877","DOI":"10.1371\/journal.pntd.0005877","article-title":"Post-kala-azar dermal leishmaniasis in the Indian subcontinent: A threat to the South-East Asia Region Kala-azar Elimination Programme","volume":"11","author":"EE Zijlstra","year":"2017","journal-title":"PLoS Negl Trop Dis"},{"key":"pntd.0011635.ref006","year":"2017","journal-title":"National Vector Borne Disease Control Programme: The Accelerated plan for Kala-azar elimination in"},{"key":"pntd.0011635.ref007","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1179\/000349802125002211","article-title":"The natural history of Sudanese post-kala-azar dermal leishmaniasis: clinical, immunological and prognostic features","volume":"96","author":"AM Musa","year":"2002","journal-title":"Ann Trop Med Parasitol"},{"key":"pntd.0011635.ref008","doi-asserted-by":"crossref","first-page":"S59","DOI":"10.1016\/S0035-9203(01)90219-6","article-title":"Leishmaniasis in Sudan. 4. Post kala-azar dermal leishmaniasis","volume":"95","author":"E Zijlstra","year":"2001","journal-title":"Transactions of the Royal Society of Tropical Medicine and Hygiene"},{"key":"pntd.0011635.ref009","unstructured":"National Centre for Vector Borne Disease Control India: Guidelines for treatment of Post-kala-azar dermal leishmaniasis (based on WHO Technical Report Series 949). New Delhi.; https:\/\/nvbdcp.gov.in\/WriteReadData\/l892s\/PKDL-Guidelines-220512.pdf."},{"key":"pntd.0011635.ref010","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1177\/0049475519877317","article-title":"Adverse ocular events on miltefosine treatment for post-kala-azar dermal leishmaniasis in India","volume":"50","author":"S Saurabh","year":"2020","journal-title":"Trop Doct"},{"key":"pntd.0011635.ref011","doi-asserted-by":"crossref","first-page":"e0007173","DOI":"10.1371\/journal.pntd.0007173","article-title":"The safety and efficacy of miltefosine in the long-term treatment of post-kala-azar dermal leishmaniasis in South Asia\u2014A review and meta-analysis","volume":"13","author":"J Pijpers","year":"2019","journal-title":"PLoS Negl Trop Dis"},{"key":"pntd.0011635.ref012","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1179\/136485905X514127","article-title":"Efficacy of liposomal amphotericin B (AmBisome) in the treatment of persistent post-kala-azar dermal leishmaniasis (PKDL).","volume":"99","author":"AM Musa","year":"2005","journal-title":"Ann Trop Med Parasitol"},{"key":"pntd.0011635.ref013","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1093\/cid\/ciy172","article-title":"Safety and Effectiveness of Short-Course AmBisome in the Treatment of Post-Kala-Azar Dermal Leishmaniasis: A Prospective Cohort Study in Bangladesh","volume":"67","author":"M den Boer","year":"2018","journal-title":"Clin Infect Dis"},{"key":"pntd.0011635.ref014","unstructured":"Short Course Regimens for Treatment of PKDL (Sudan). [https:\/\/clinicaltrials.gov\/show\/NCT03399955]"},{"key":"pntd.0011635.ref015","doi-asserted-by":"crossref","first-page":"e371","DOI":"10.1016\/S2214-109X(13)70078-0","article-title":"The drug and vaccine landscape for neglected diseases (2000\u201311): a systematic assessment.","volume":"1","author":"B Pedrique","year":"2013","journal-title":"Lancet Glob Health"},{"key":"pntd.0011635.ref016","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1093\/cid\/ciy891","article-title":"Quantifying the Infectiousness of Post-Kala-Azar Dermal Leishmaniasis Toward Sand Flies","volume":"69","author":"D Mondal","year":"2019","journal-title":"Clin Infect Dis"},{"key":"pntd.0011635.ref017","doi-asserted-by":"crossref","first-page":"e23","DOI":"10.1016\/S2666-5247(20)30166-X","article-title":"Xenodiagnosis to evaluate the infectiousness of humans to sandflies in an area endemic for visceral leishmaniasis in Bihar, India: a transmission-dynamics study","volume":"2","author":"OP Singh","year":"2021","journal-title":"Lancet Microbe"},{"key":"pntd.0011635.ref018","doi-asserted-by":"crossref","first-page":"34","DOI":"10.4103\/ijd.IJD_264_20","article-title":"Therapeutic Modalities in Post Kala-azar Dermal Leishmaniasis: A Systematic Review of the Effectiveness and Safety of the Treatment Options","volume":"66","author":"A Datta","year":"2021","journal-title":"Indian J Dermatol"},{"key":"pntd.0011635.ref019","doi-asserted-by":"crossref","first-page":"467","DOI":"10.7326\/M18-0850","article-title":"PRISMA Extension for Scoping Reviews (PRISMA-ScR): Checklist and Explanation","volume":"169","author":"AC Tricco","year":"2018","journal-title":"Ann Intern Med"},{"key":"pntd.0011635.ref020","unstructured":"Covidence systematic review software, Veritas Health Innovation, Melbourne, Australia. Available from www.covidence.org."},{"key":"pntd.0011635.ref021","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1016\/j.jbi.2008.08.010","article-title":"Research electronic data capture (REDCap)\u2014a metadata-driven methodology and workflow process for providing translational research informatics support.","volume":"42","author":"PA Harris","year":"2009","journal-title":"J Biomed Inform"},{"key":"pntd.0011635.ref022","doi-asserted-by":"crossref","first-page":"103208","DOI":"10.1016\/j.jbi.2019.103208","article-title":"The REDCap consortium: Building an international community of software platform partners","volume":"95","author":"PA Harris","year":"2019","journal-title":"J Biomed Inform"},{"key":"pntd.0011635.ref023","first-page":"575","volume":"97","author":"Mondiale de la Sant\u00e9 O, World Health Organization: Global leishmaniasis surveillance: 2021, assessing the impact of the COVID-19 pandemic\u2013Surveillance mondiale de la leishmaniose: 2021, \u00e9valuation de l\u2019impact de la pand\u00e9mie de COVID-19","year":"2022","journal-title":"Weekly Epidemiological Record = Relev\u00e9 \u00e9pid\u00e9miologique hebdomadaire"},{"key":"pntd.0011635.ref024","doi-asserted-by":"crossref","first-page":"e250","DOI":"10.1111\/ijd.13048","article-title":"A male preponderance in patients with Indian post kala-azar dermal leishmaniasis is associated with increased circulating levels of testosterone","volume":"55","author":"D Mukhopadhyay","year":"2016","journal-title":"Int J Dermatol"},{"key":"pntd.0011635.ref025","doi-asserted-by":"crossref","first-page":"e0007995","DOI":"10.1371\/journal.pntd.0007995","article-title":"Male predominance in reported Visceral Leishmaniasis cases: Nature or nurture? A comparison of population-based with health facility-reported data","volume":"14","author":"K Cloots","year":"2020","journal-title":"PLoS Negl Trop Dis"},{"key":"pntd.0011635.ref026","doi-asserted-by":"crossref","first-page":"e0009204","DOI":"10.1371\/journal.pntd.0009204","article-title":"Gender disparity in cases enrolled in clinical trials of visceral leishmaniasis: A systematic review and meta-analysis","volume":"15","author":"P Dahal","year":"2021","journal-title":"PLoS Negl Trop Dis"},{"key":"pntd.0011635.ref027","doi-asserted-by":"crossref","first-page":"1501","DOI":"10.1111\/j.1365-4632.2012.05810.x","article-title":"Post-kala-azar dermal leishmaniasis in pregnancy: hitherto unaccounted","volume":"53","author":"P Verma","year":"2014","journal-title":"International Journal of Dermatology"},{"key":"pntd.0011635.ref028","doi-asserted-by":"crossref","first-page":"e0009650","DOI":"10.1371\/journal.pntd.0009650","article-title":"Visceral Leishmaniasis in pregnancy and vertical transmission: A systematic literature review on the therapeutic orphans","volume":"15","author":"P Dahal","year":"2021","journal-title":"PLoS Negl Trop Dis"},{"key":"pntd.0011635.ref029","doi-asserted-by":"crossref","first-page":"1423","DOI":"10.1093\/cid\/ciac127","article-title":"AmBisome Monotherapy and Combination AmBisome\u2013Miltefosine Therapy for the Treatment of Visceral Leishmaniasis in Patients Coinfected With Human Immunodeficiency Virus in India: A Randomized Open-Label, Parallel-Arm, Phase 3 Trial","volume":"75","author":"S Burza","year":"2022","journal-title":"Clinical Infectious Diseases"},{"key":"pntd.0011635.ref030","first-page":"1","article-title":"Co-infection of tuberculosis and parasitic diseases in humans: a systematic review","volume":"6","author":"X-X Li","year":"2013","journal-title":"Parasites & vectors"},{"key":"pntd.0011635.ref031","author":"WH Organization","year":"2013","journal-title":"Post-kala-azar dermal leishmaniasis: a manual for case management and control: report of a WHO consultative meeting, Kolkata, India, 2\u20133 July 2012"},{"key":"pntd.0011635.ref032","article-title":"Post-kala-azar dermal leishmaniasis (PKDL), HIV and pulmonary tuberculosis","volume":"23","author":"V Das","year":"2010","journal-title":"The National medical journal of India"},{"key":"pntd.0011635.ref033","doi-asserted-by":"crossref","first-page":"e3258","DOI":"10.1371\/journal.pntd.0003258","article-title":"PKDL and other dermal lesions in HIV co-infected patients with leishmaniasis: review of clinical presentation in relation to immune responses","volume":"8","author":"EE Zijlstra","year":"2014","journal-title":"PLoS neglected tropical diseases"},{"key":"pntd.0011635.ref034","doi-asserted-by":"crossref","first-page":"2257","DOI":"10.4269\/ajtmh.20-0301","article-title":"False positivity of rK39 test in five chronic myeloid leukemia cases from Bihar, India: a possible challenge to leishmaniasis diagnosis","volume":"103","author":"RK Topno","year":"2020","journal-title":"The American Journal of Tropical Medicine and Hygiene"},{"key":"pntd.0011635.ref035","doi-asserted-by":"crossref","first-page":"e0009302","DOI":"10.1371\/journal.pntd.0009302","article-title":"Serious adverse events following treatment of visceral leishmaniasis: A systematic review and meta-analysis","volume":"15","author":"S Singh-Phulgenda","year":"2021","journal-title":"PLoS Negl Trop Dis"},{"key":"pntd.0011635.ref036","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1016\/0140-6736(93)93004-K","article-title":"Meta-analysis of the literature or of individual patient data: is there a difference?","volume":"341","author":"LA Stewart","year":"1993","journal-title":"The Lancet"},{"key":"pntd.0011635.ref037","doi-asserted-by":"crossref","first-page":"e1001855","DOI":"10.1371\/journal.pmed.1001855","article-title":"Individual participant data (IPD) meta-analyses of randomised controlled trials: guidance on their use","volume":"12","author":"JF Tierney","year":"2015","journal-title":"PLoS medicine"},{"key":"pntd.0011635.ref038","article-title":"Comparing the overall result and interaction in aggregate data meta-analysis and individual patient data meta-analysis","volume":"95","author":"Y Huang","year":"2016","journal-title":"Medicine"},{"key":"pntd.0011635.ref039","doi-asserted-by":"crossref","first-page":"ofad231","DOI":"10.1093\/ofid\/ofad231","article-title":"Safety and Effectiveness of Miltefosine in Post-Kala-Azar Dermal Leishmaniasis: An Observational Study","volume":"10","author":"S Sundar","year":"2023","journal-title":"Open Forum Infect Dis"},{"key":"pntd.0011635.ref040","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1186\/s12916-015-0445-x","article-title":"Talisuna AO: Clinical determinants of early parasitological response to ACTs in African patients with uncomplicated falciparum malaria: a literature review and meta-analysis of individual patient data","volume":"13","author":"Group WAbCTABS","year":"2015","journal-title":"BMC Med"},{"key":"pntd.0011635.ref041","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1186\/s12916-015-0301-z","article-title":"The effect of dosing strategies on the therapeutic efficacy of artesunate-amodiaquine for uncomplicated malaria: a meta-analysis of individual patient data.","volume":"13","author":"WorldWide Antimalarial Resistance Network ASAQSG","year":"2015","journal-title":"BMC Med"},{"key":"pntd.0011635.ref042","doi-asserted-by":"crossref","first-page":"e1001564","DOI":"10.1371\/journal.pmed.1001564","volume":"10","author":"WorldWide Antimalarial Resistance Network DPSG: The effect of dosing regimens on the antimalarial efficacy of dihydroartemisinin-piperaquine: a pooled analysis of individual patient data.","year":"2013","journal-title":"PLoS Med"},{"key":"pntd.0011635.ref043","unstructured":"CDISC compliant case report forms for uncomplicated VL and VL-HIV co-infection: A unique collaborative effort by VL experts and a first in NTDs [https:\/\/www.iddo.org\/news\/cdisc-compliant-case-report-forms-uncomplicated-vl-and-vl-hiv-co-infection-unique] [24 August 2023]"},{"key":"pntd.0011635.ref044","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1080\/00034983.1997.11813179","article-title":"Amphotericin B is superior to sodium antimony gluconate in the treatment of Indian post-kala-azar dermal leishmaniasis","volume":"91","author":"CP Thakur","year":"1997","journal-title":"Ann Trop Med Parasitol"},{"key":"pntd.0011635.ref045","doi-asserted-by":"crossref","first-page":"34","DOI":"10.25259\/IJDVL_410_19","article-title":"A randomized, open-label study to evaluate the efficacy and safety of liposomal amphotericin B (AmBisome) versus miltefosine in patients with post-kala-azar dermal leishmaniasis","volume":"87","author":"K Pandey","year":"2021","journal-title":"Indian J Dermatol Venereol Leprol"},{"key":"pntd.0011635.ref046","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1016\/j.trstmh.2007.08.006","article-title":"Immunochemotherapy of persistent post-kala-azar dermal leishmaniasis: a novel approach to treatment","volume":"102","author":"AM Musa","year":"2008","journal-title":"Trans R Soc Trop Med Hyg"},{"key":"pntd.0011635.ref047","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1111\/bjd.15119","article-title":"Safety and efficacy of a combination of paromomycin and miltefosine for two vs. three courses in patients with post-kala-azar dermal leishmaniasis: an observational pilot study","volume":"177","author":"K Pandey","year":"2017","journal-title":"Br J Dermatol"},{"key":"pntd.0011635.ref048","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1111\/tmi.12015","article-title":"Oral miltefosine for Indian post-kala-azar dermal leishmaniasis: a randomised trial","volume":"18","author":"S Sundar","year":"2013","journal-title":"Trop Med Int Health"},{"key":"pntd.0011635.ref049","doi-asserted-by":"crossref","first-page":"886","DOI":"10.1136\/bmj.295.6603.886-a","article-title":"Treatment of post-kala-azar dermal leishmaniasis with sodium stibogluconate","volume":"295","author":"CP Thakur","year":"1987","journal-title":"Br Med J (Clin Res Ed)"},{"key":"pntd.0011635.ref050","article-title":"Therapeutic trial of sodium antimony gluconate alone and in combination with ketoconazole in post-kala-azar dermal leishmaniasis (PKDL)","volume":"69","author":"S Rathi","year":"2003","journal-title":"Indian J Dermatol Venereol Leprol"},{"key":"pntd.0011635.ref051","doi-asserted-by":"crossref","first-page":"e0174497","DOI":"10.1371\/journal.pone.0174497","article-title":"To evaluate efficacy and safety of amphotericin B in two different doses in the treatment of post kala-azar dermal leishmaniasis (PKDL)","volume":"12","author":"VN Rabi Das","year":"2017","journal-title":"PLoS One"},{"key":"pntd.0011635.ref052","first-page":"161","article-title":"Immune response and drug response in kala-azar and Post kala-azar dermal leishmaniasis.","author":"A Nandy","year":"1983","journal-title":"Proceedings of the Indo-UK workshop"},{"key":"pntd.0011635.ref053","doi-asserted-by":"crossref","first-page":"201","DOI":"10.25259\/IJDVL_338_20","article-title":"Liposomal amphotericin B is more effective in polymorphic lesions of post kala-azar dermal leishmaniasis","volume":"88","author":"S Moulik","year":"2022","journal-title":"Indian J Dermatol Venereol Leprol"},{"key":"pntd.0011635.ref054","doi-asserted-by":"crossref","first-page":"2366","DOI":"10.1016\/j.ymthe.2021.03.020","article-title":"Safety and immunogenicity of ChAd63-KH vaccine in post-kala-azar dermal leishmaniasis patients in Sudan","volume":"29","author":"BM Younis","year":"2021","journal-title":"Mol Ther"},{"key":"pntd.0011635.ref055","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1016\/S0035-9203(96)90134-0","article-title":"Failure of a combination of two antifungal drugs, terbinafine plus itraconazole, in Sudanese post kala-azar dermal leishmaniasis","volume":"90","author":"EA Khalil","year":"1996","journal-title":"Trans R Soc Trop Med Hyg"},{"key":"pntd.0011635.ref056","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.1038\/jid.2009.393","article-title":"Enhanced lesional Foxp3 expression and peripheral anergic lymphocytes indicate a role for regulatory T cells in Indian post-kala-azar dermal leishmaniasis","volume":"130","author":"S Ganguly","year":"2010","journal-title":"J Invest Dermatol"},{"key":"pntd.0011635.ref057","doi-asserted-by":"crossref","first-page":"345","DOI":"10.4269\/ajtmh.12-0711","article-title":"Clinical and immunological aspects of post-kala-azar dermal leishmaniasis in Bangladesh","volume":"89","author":"S Islam","year":"2013","journal-title":"Am J Trop Med Hyg"},{"key":"pntd.0011635.ref058","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1080\/00034983.1988.11812205","article-title":"Modulation of the cell-mediated immune response in kala-azar and post-kala-azar dermal leishmaniasis in relation to chemotherapy","volume":"82","author":"AB Neogy","year":"1988","journal-title":"Ann Trop Med Parasitol"},{"key":"pntd.0011635.ref059","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1111\/exd.12635","article-title":"Decreased presence of Langerhans cells is a critical determinant for Indian Post kala-azar dermal leishmaniasis","volume":"24","author":"S Mukherjee","year":"2015","journal-title":"Exp Dermatol"},{"key":"pntd.0011635.ref060","doi-asserted-by":"crossref","first-page":"762","DOI":"10.1038\/s41598-018-37144-y","article-title":"Impaired activation of lesional CD8(+) T-cells is associated with enhanced expression of Programmed Death-1 in Indian Post Kala-azar Dermal Leishmaniasis","volume":"9","author":"S Mukherjee","year":"2019","journal-title":"Sci Rep"},{"key":"pntd.0011635.ref061","doi-asserted-by":"crossref","first-page":"e1657","DOI":"10.1371\/journal.pntd.0001657","article-title":"Drug susceptibility in Leishmania isolates following miltefosine treatment in cases of visceral leishmaniasis and post kala-azar dermal leishmaniasis","volume":"6","author":"V Bhandari","year":"2012","journal-title":"PLoS Negl Trop Dis"},{"key":"pntd.0011635.ref062","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1016\/0035-9203(90)90381-N","article-title":"Leishmanin test in post-kala-azar dermal leishmaniasis","volume":"84","author":"AB Neogy","year":"1990","journal-title":"Trans R Soc Trop Med Hyg"},{"key":"pntd.0011635.ref063","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1016\/0035-9203(92)90294-M","article-title":"Post kala-azar dermal leishmaniasis in the Sudan: clinical features, pathology and treatment","volume":"86","author":"AM el Hassan","year":"1992","journal-title":"Trans R Soc Trop Med Hyg"},{"key":"pntd.0011635.ref064","first-page":"619","article-title":"Use of rK39 for diagnosis of post kala-azar dermal leishmaniasis in Nepal","volume":"38","author":"ML Das","year":"2007","journal-title":"Southeast Asian J Trop Med Public Health"},{"key":"pntd.0011635.ref065","doi-asserted-by":"crossref","first-page":"e1171","DOI":"10.1371\/journal.pntd.0001171","article-title":"Foxp3 and IL-10 expression correlates with parasite burden in lesional tissues of post kala azar dermal leishmaniasis (PKDL) patients","volume":"5","author":"GK Katara","year":"2011","journal-title":"PLoS Negl Trop Dis"},{"key":"pntd.0011635.ref066","first-page":"328","article-title":"Miltefosine Induced Reduced Male Fertility Capacity after Treatment of Post Kala-azar Dermal Leishmaniasis, Bangladesh","volume":"28","author":"A Basher","year":"2019","journal-title":"Mymensingh Med J"},{"key":"pntd.0011635.ref067","doi-asserted-by":"crossref","first-page":"e0004138","DOI":"10.1371\/journal.pntd.0004138","article-title":"PKDL\u2014A Silent Parasite Pool for Transmission of Leishmaniasis in Kala-azar Endemic Areas of Malda District, West Bengal, India","volume":"9","author":"S Ganguly","year":"2015","journal-title":"PLoS Negl Trop Dis"},{"key":"pntd.0011635.ref068","doi-asserted-by":"crossref","first-page":"e0185606","DOI":"10.1371\/journal.pone.0185606","article-title":"Real-time PCR in detection and quantitation of Leishmania donovani for the diagnosis of Visceral Leishmaniasis patients and the monitoring of their response to treatment.","volume":"12","author":"F Hossain","year":"2017","journal-title":"PLoS One"},{"key":"pntd.0011635.ref069","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1016\/0035-9203(93)90140-L","article-title":"The treatment of kala-azar in the Sudan with sodium stibogluconate: a randomized trial of three dosage regimens","volume":"87","author":"EE Zijlstra","year":"1993","journal-title":"Trans R Soc Trop Med Hyg"},{"key":"pntd.0011635.ref070","first-page":"199","article-title":"Miltefosine in post-kala-azar dermal Leishmaniasis (PKDL)","volume":"11","author":"D Modak","year":"2010","journal-title":"J Indian Acad Clin Med"},{"key":"pntd.0011635.ref071","doi-asserted-by":"crossref","first-page":"ofy234","DOI":"10.1093\/ofid\/ofy234","article-title":"Evaluation of Real-time PCR for Diagnosis of Post-Kala-azar Dermal Leishmaniasis in Endemic Foci of Bangladesh","volume":"5","author":"P Ghosh","year":"2018","journal-title":"Open Forum Infect Dis"},{"key":"pntd.0011635.ref072","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1046\/j.1365-3156.2002.00832.x","article-title":"Epidemiology and clinical manifestations of Leishmania donovani infection in two villages in an endemic area in eastern Sudan","volume":"7","author":"EA Khalil","year":"2002","journal-title":"Trop Med Int Health"},{"key":"pntd.0011635.ref073","doi-asserted-by":"crossref","first-page":"e0004093","DOI":"10.1371\/journal.pntd.0004093","article-title":"Decline in Clinical Efficacy of Oral Miltefosine in Treatment of Post Kala-azar Dermal Leishmaniasis (PKDL) in India","volume":"9","author":"V Ramesh","year":"2015","journal-title":"PLoS Negl Trop Dis"},{"key":"pntd.0011635.ref074","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1016\/j.intimp.2017.06.010","article-title":"Cathelicidin augments VDR-dependent anti-leishmanial immune response in Indian Post-Kala-Azar Dermal Leishmaniasis","volume":"50","author":"S Das","year":"2017","journal-title":"Int Immunopharmacol"},{"key":"pntd.0011635.ref075","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1007\/s10875-015-0215-8","article-title":"Decreased Frequency and Secretion of CD26 Promotes Disease Progression in Indian Post Kala-azar Dermal Leishmaniasis","volume":"36","author":"S Mukherjee","year":"2016","journal-title":"J Clin Immunol"},{"key":"pntd.0011635.ref076","doi-asserted-by":"crossref","first-page":"e0192302","DOI":"10.1371\/journal.pone.0192302","article-title":"Glycoproteins in circulating immune complexes are biomarkers of patients with Indian PKDL: A study from endemic districts of West Bengal, India","volume":"13","author":"P Jaiswal","year":"2018","journal-title":"PLoS One"},{"key":"pntd.0011635.ref077","doi-asserted-by":"crossref","first-page":"299","DOI":"10.4269\/ajtmh.1995.52.299","article-title":"Endemic kala-azar in eastern Sudan: post-kala-azar dermal leishmaniasis","volume":"52","author":"EE Zijlstra","year":"1995","journal-title":"Am J Trop Med Hyg"},{"key":"pntd.0011635.ref078","doi-asserted-by":"crossref","first-page":"548010","DOI":"10.1155\/2014\/548010","article-title":"Efficacy and Safety of Paromomycin in Treatment of Post-Kala-Azar Dermal Leishmaniasis","volume":"2014","author":"S Sundar","year":"2014","journal-title":"ISRN Parasitol"},{"key":"pntd.0011635.ref079","doi-asserted-by":"crossref","first-page":"414378","DOI":"10.1155\/2015\/414378","article-title":"Efficacy and safety of miltefosine in treatment of post-kala-azar dermal leishmaniasis","volume":"2015","author":"S Sundar","year":"2015","journal-title":"ScientificWorldJournal"},{"key":"pntd.0011635.ref080","doi-asserted-by":"crossref","first-page":"767","DOI":"10.4269\/ajtmh.14-0721","article-title":"Inadequacy of 12-Week Miltefosine Treatment for Indian Post-Kala-Azar Dermal Leishmaniasis","volume":"93","author":"S Ghosh","year":"2015","journal-title":"Am J Trop Med Hyg"},{"key":"pntd.0011635.ref081","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1046\/j.1365-4362.2001.01198.x","article-title":"Post-kala-azar dermal leishmaniasis in Nepal","volume":"40","author":"VK Garg","year":"2001","journal-title":"Int J Dermatol"},{"key":"pntd.0011635.ref082","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1111\/j.1365-4362.1993.tb04266.x","article-title":"Post-kala-azar dermal leishmaniasis: a clinical and therapeutic study.","volume":"32","author":"V Ramesh","year":"1993","journal-title":"Int J Dermatol"},{"key":"pntd.0011635.ref083","doi-asserted-by":"crossref","first-page":"1762","DOI":"10.1086\/588387","article-title":"Increased levels of interleukin-10 and IgG3 are hallmarks of Indian post-kala-azar dermal leishmaniasis","volume":"197","author":"S Ganguly","year":"2008","journal-title":"J Infect Dis"},{"key":"pntd.0011635.ref084","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1111\/tmi.12047","article-title":"Reliable diagnosis of post-kala-azar dermal leishmaniasis (PKDL) using slit aspirate specimen to avoid invasive sampling procedures","volume":"18","author":"S Verma","year":"2013","journal-title":"Trop Med Int Health"},{"key":"pntd.0011635.ref085","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1093\/cid\/cix808","article-title":"Monitoring of Parasite Kinetics in Indian Post-Kala-azar Dermal Leishmaniasis","volume":"66","author":"S Moulik","year":"2018","journal-title":"Clin Infect Dis"},{"key":"pntd.0011635.ref086","doi-asserted-by":"crossref","first-page":"608","DOI":"10.1093\/infdis\/jiz486","article-title":"Assessing the Efficacy and Safety of Liposomal Amphotericin B and Miltefosine in Combination for Treatment of Post Kala-Azar Dermal Leishmaniasis","volume":"221","author":"V Ramesh","year":"2020","journal-title":"J Infect Dis"},{"key":"pntd.0011635.ref087","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1111\/j.1365-2133.2011.10402.x","article-title":"Miltefosine as an effective choice in the treatment of post-kala-azar dermal leishmaniasis","volume":"165","author":"V Ramesh","year":"2011","journal-title":"Br J Dermatol"},{"key":"pntd.0011635.ref088","article-title":"Post-kala-azar dermal leishmaniasis (PKDL) in visceral leishmaniasis-endemic communities in Bihar, India","author":"RP Singh","year":"2012","journal-title":"Trop Med Int Health"},{"key":"pntd.0011635.ref089","doi-asserted-by":"crossref","first-page":"390","DOI":"10.4269\/ajtmh.1991.44.390","article-title":"Positive response to sodium antimony gluconate administration in visceral leishmaniasis seropositive patients","volume":"44","author":"S Chowdhury","year":"1991","journal-title":"Am J Trop Med Hyg"},{"key":"pntd.0011635.ref090","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1111\/j.1365-4362.1992.tb02668.x","article-title":"Post-kala-azar dermal leishmaniasis in the Sudan: peripheral neural involvement.","volume":"31","author":"AM Elhassan","year":"1992","journal-title":"Int J Dermatol"},{"key":"pntd.0011635.ref091","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/S0035-9203(99)90291-2","article-title":"Serodiagnosis of Leishmania donovani infections: assessment of enzyme-linked immunosorbent assays using recombinant L. donovani gene B protein (GBP) and a peptide sequence of L. donovani GBP","volume":"93","author":"AT Jensen","year":"1999","journal-title":"Trans R Soc Trop Med Hyg"},{"key":"pntd.0011635.ref092","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1002\/(SICI)1096-9896(199912)189:4<615::AID-PATH466>3.0.CO;2-Z","article-title":"Immunopathology of post kala-azar dermal leishmaniasis (PKDL): T-cell phenotypes and cytokine profile","volume":"189","author":"A Ismail","year":"1999","journal-title":"J Pathol"},{"key":"pntd.0011635.ref093","first-page":"144","article-title":"Efficacy of prolonged therapy with stibogluconate in post kala-azar dermal leishmaniasis","volume":"91","author":"CP Thakur","year":"1990","journal-title":"Indian J Med Res"},{"key":"pntd.0011635.ref094","doi-asserted-by":"crossref","first-page":"e0009906","DOI":"10.1371\/journal.pntd.0009906","article-title":"IgG3 and IL10 are effective biomarkers for monitoring therapeutic effectiveness in Post Kala-Azar Dermal Leishmaniasis","volume":"15","author":"S Sengupta","year":"2021","journal-title":"PLoS neglected tropical diseases"},{"key":"pntd.0011635.ref095","doi-asserted-by":"crossref","first-page":"e0011780","DOI":"10.1371\/journal.pntd.0011780","article-title":"Safety and efficacy of paromomycin\/miltefosine\/liposomal amphotericin B combinations for the treatment of post-kala-azar dermal leishmaniasis in Sudan: A phase II, open label, randomized, parallel arm study","volume":"17","author":"BM Younis","year":"2023","journal-title":"PLoS Negl Trop Dis"}],"updated-by":[{"DOI":"10.1371\/journal.pntd.0011635","type":"new_version","label":"New version","source":"publisher","updated":{"date-parts":[[2024,4,26]],"date-time":"2024-04-26T00:00:00Z","timestamp":1714089600000}}],"container-title":["PLOS Neglected Tropical Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pntd.0011635","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,4,26]],"date-time":"2024-04-26T13:42:52Z","timestamp":1714138972000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pntd.0011635"}},"subtitle":[],"editor":[{"given":"Ana Laura","family":"Grossi de Oliveira","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2024,4,16]]},"references-count":95,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2024,4,16]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pntd.0011635","relation":{"has-preprint":[{"id-type":"doi","id":"10.1101\/2023.09.06.23295006","asserted-by":"object"}]},"ISSN":["1935-2735"],"issn-type":[{"value":"1935-2735","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,4,16]]}}}